Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription 15.09.2025 5 BJU Int 1 BMC Urol 1 Clin Cancer Res 1 Eur Radiol 3 Eur Urol 1 Int J Cancer 5 Int J Radiat Oncol Biol Phys 1 J Nucl Med 2 J Urol 1 JAMA 1 PLoS One 2 Prostate 1 Radiol Artif Intell 1 Urology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BJU Int

1. LEWICKI P, Ginsburg K, Mmonu N, Labardee C, et al
   What is lost in an average? Identifying distinct post-radical prostatectomy functional recovery profiles.
   BJU Int. 2025;136:633-639.
   PubMed         Abstract available
   
   
2. ZAURITO P, Westerberg M, Garmo H, Gedeborg R, et al
   Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom Score.
   BJU Int. 2025 Sep 12. doi: 10.1111/bju.16927.
   PubMed         Abstract available
   
   
3. BYRNE MHV, Anbarasan T, Browning L, Woodcock DJ, et al
   What spatial omics is teaching us about field cancerisation in prostate and bladder cancer.
   BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830.
   PubMed         Abstract available
   
   
4. HALL R, Ball R, Bancroft E, Eeles R, et al
   Systematic review of PSA reference intervals in the gender diverse population with prostates.
   BJU Int. 2025;136:568-577.
   PubMed         Abstract available
   
   
5. VISSCHER J, Bonevski B, O'Callaghan M
   The association of smoking with urinary and sexual function recovery following radical prostatectomy.
   BJU Int. 2025;136:647-656.
   PubMed         Abstract available
   
   

   
   BMC Urol

6. INOUE K, Shinohara M, Saka T, Hirao Y, et al
   Correction: Evaluation of the changes in hydrogel spacer volume in patients treated with proton therapy for prostate cancer.
   BMC Urol. 2025;25:228.
   PubMed        
   
   

   
   Clin Cancer Res

7. BLINKA S, Yu EY
   Drug targets in prostate cancer: an appetite for KLK2-mediated destruction.
   Clin Cancer Res. 2025 Sep 9. doi: 10.1158/1078-0432.CCR-25-2546.
   PubMed         Abstract available
   
   

   
   Eur Radiol

8. GIROMETTI R, Peruzzi V, Clauser P, Potsch N, et al
   Diffusion levels for quantitative assessment of the apparent diffusion coefficient value in prostate MRI: a proof-of-concept bicentric study.
   Eur Radiol. 2025;35:6171-6182.
   PubMed         Abstract available
   
   

   
   Eur Urol

9. LI S, Wang C
   Re: Sarah Burdett, David J Fisher, Jayne F. Tierney, et al. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data. Eur Urol.
   Eur Urol. 2025 Sep 6:S0302-2838(25)00480-4. doi: 10.1016/j.eururo.2025.
   PubMed        
   
   
10. LI J, Zhang Y, Hu H
    Re: Metformin for Patients with Metastatic Prostate Cancer Starting Androgen Deprivation Therapy: A Randomised Phase 3 Trial of the STAMPEDE Platform Protocol.
    Eur Urol. 2025 Sep 8:S0302-2838(25)00483-X. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    
11. DU Y, Liu D, Guan Z
    Re: Cameron Englman, Busola Adebusoye, Davide Maffei, et al. Magnetic Resonance Imaging-led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.03.0
    Eur Urol. 2025 Sep 9:S0302-2838(25)00478-6. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    

    
    Int J Cancer

12. LIN E, Garmo H, Beckmann K, Bratt O, et al
    Prostate cancer characteristics in fathers and risk of early onset high-risk prostate cancer in sons.
    Int J Cancer. 2025 Sep 9. doi: 10.1002/ijc.70133.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

13. TISSEVERASINGHE S, Niazi T
    Pelvic Nodal Irradiation Should Be Offered to High-Risk Prostate Cancer Patients Receiving Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2025;123:387-391.
    PubMed        
    
    
14. ACHARD V, Benziane-Ouaritini N, Sargos P
    Hypofractionated Radiation Therapy for Prostate Cancer in the Postoperative Setting: Is It Capable of Going the Distance?
    Int J Radiat Oncol Biol Phys. 2025;123:381-383.
    PubMed        
    
    
15. RAMADAN S, Loblaw A, Dhar A, Fakir H, et al
    PSMA MRI Guided prOstate SBRT (ARGOS)/Comprehensive, Longitudinal Evaluation of IMaging BiomarkErs Post Radiotherapy (CLIMBER) Phase I/II Trial.
    Int J Radiat Oncol Biol Phys. 2025;123:395-405.
    PubMed         Abstract available
    
    
16. RANTA K, Wojcieszynski AP, Zhao SG, Liu Y, et al
    Severe Late Toxicities (Grade 3-5) With 13 Years of Follow-up after Hypofractionated Postprostatectomy Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2025;123:374-380.
    PubMed         Abstract available
    
    
17. SAAD E, Hoskin P, Choudhury A
    Prophylactic Pelvic Nodal Radiation Therapy in High-risk Node-negative Prostate Cancer: The Case Against.
    Int J Radiat Oncol Biol Phys. 2025;123:392-394.
    PubMed        
    
    

    
    J Nucl Med

18. BEINTNER-SKAWRAN S, Gafita A, Lorenzini T, Tauber R, et al
    [(68)Ga]Ga-PSMA-11 PET Tumor Volume Predicts Overall Survival of Patients with Metastatic Prostate Cancer Undergoing Taxane-Based Chemotherapy.
    J Nucl Med. 2025 Sep 11:jnumed.125.269584. doi: 10.2967/jnumed.125.269584.
    PubMed         Abstract available
    
    

    
    J Urol

19. DASKIVICH TJ, Stock SR, Cummings S, Masterson JM, et al
    Risks of Progression After Early Androgen Deprivation Therapy for Biochemical Recurrence After Radical Prostatectomy.
    J Urol. 2025;214:354-364.
    PubMed         Abstract available
    
    
20. FREITAS PFS, Khandekar A, Porto JG, Yu H, et al
    Can Genomic Classifiers in Biopsy Cores With Grade Group 1 Cancer Predict Higher-Grade Disease Elsewhere in the Prostate? Results From the Prospective Miami Active Surveillance Trial.
    J Urol. 2025;214:383-392.
    PubMed         Abstract available
    
    

    
    JAMA

21. NG ABCD, Asif A, Agarwal R, Panebianco V, et al
    Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial.
    JAMA. 2025 Sep 10:e2513722. doi: 10.1001/jama.2025.13722.
    PubMed         Abstract available
    
    

    
    PLoS One

22. BACH CA, Hossain MN, Chaudhari IJ, Verrillo CE, et al
    A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer.
    PLoS One. 2025;20:e0329014.
    PubMed         Abstract available
    
    

    
    Prostate

23. HUNT TC, Malshy K, Steidle M, Li A, et al
    Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized Prostate Cancer.
    Prostate. 2025 Sep 9. doi: 10.1002/pros.70043.
    PubMed         Abstract available
    
    
24. FALKENBACH F, Di Bello F, Penaranda NR, Longoni M, et al
    USPSTF Recommendation Against PSA Screening vs. Stage and Cancer-Specific Mortality in Localized Prostate Cancer.
    Prostate. 2025 Sep 9. doi: 10.1002/pros.70045.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

25. MORADI A, Zerka F, Bosma JS, Sunoqrot MRS, et al
    Optimizing Federated Learning Configurations for MRI Prostate Segmentation and Cancer Detection: A Simulation Study.
    Radiol Artif Intell. 2025 Jul 30:e240485. doi: 10.1148/ryai.240485.
    PubMed         Abstract available
    
    

    
    Urology

26. MARTIN C, Maoate K, Hooshyari A, Ordones FV, et al
    Transitioning to Office-based Transperineal Prostate Biopsy-A Case Study From a Regional New Zealand Hospital in Economic and Environmental Sustainability.
    Urology. 2025;203:53-59.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.